Federal Circuit Affirms Aventis' Inequitable Conduct

Law360, New York (May 14, 2008, 12:00 AM EDT) -- A federal appeals court has affirmed a lower court ruling that found Sanofi-Aventis’ patents for its anti-clotting drug Lovenox invalid due to inequitable conduct, allowing generic versions of the drug to make their way toward the U.S. market.

In a 2-1 decision Wednesday, the U.S. Court of Appeals for the Federal Circuit upheld a district court’s February 2007 decision in favor of generics makers Amphastar Pharmaceuticals Inc. and Teva Pharmaceuticals USA Inc., which Sanofi-Aventis subsidiaries Aventis Pharma SA and Aventis Pharmaceutical Inc. had sued for patent...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.